Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Duragesic Shortage Resolved

This article was originally published in The Pink Sheet Daily

Executive Summary

Short supply issues for Janssen's opioid analgesic transdermal patch are resolved. The company recalled lots of Duragesic in February and April due to possible medication leakage along one edge.

You may also be interested in...

FDA Cites J&J Duragesic Promotion For Misleading Safety Profile

Reports from a national drug abuse surveillance database are not sufficient basis for comparative safety claims between the Duragesic patch and other pain agents, FDA says. The agency asks J&J to devise a corrective action plan for a violative professional file card that was distributed beginning in 2003.

Janssen Expands Duragesic Recall

Additional lots of the 75 mcg/hour patches might leak medication along one edge. The recall now includes five lots of the chronic pain therapy shipped between December 2003 and March 2004.

Janssen Duragesic Recall





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts